Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CT Glaucoma Associates
Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later.
At each study visit, dry eye signs will be assessed and brief dry eye survey will be administered.
Age
25–90
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Adult glaucoma patients who are taking drops: dor-tim and Latanoprost Ophthalmic Solution 0.005% (Lat) and come in for an appointment during the trial period
You may not be if
The final determination to be included in the study will be made by the Physician on the day of the appointment.